BusinessMyoKardia Announces Appointment of Taylor C. Harris as Chief Financial OfficerBy Nasdaq OMXApr 4, 2018, 12:31 PM UTC
BusinessMyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy PatientsBy Nasdaq OMXApr 2, 2018, 12:31 PM UTC
BusinessMyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy PatientsBy Nasdaq OMXMar 8, 2018, 9:02 PM UTC
BusinessMyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy PatientsBy Nasdaq OMXFeb 14, 2018, 1:30 PM UTC
BusinessMyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable BiosensorBy Nasdaq OMXNov 14, 2017, 12:15 AM UTC
BusinessMyoKardia Announces Pricing of Proposed Public Offering of Common StockBy Nasdaq OMXSep 27, 2016, 10:48 PM UTC
BusinessMyoKardia Announces Proposed Public Offering of Common StockBy Nasdaq OMXSep 26, 2016, 8:48 PM UTC
